



Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): blocking 5HT₃ receptors enhances release of serotonin, norepinephrine, and acetylcholine

Stephen M. Stahl

ISSUE:

Vortioxetine is an antidepressant with multiple pharmacologic modes of action at targets where serotonin neurons connect with other neurons. 5HT₃ receptor antagonism is one of these actions, and this leads to increased release of norepinephrine (NE), acetylcholine (ACh), and serotonin (5HT) within various brain circuits.

Take-Home Points

- Vortioxetine is an antagonist at serotonin (5HT) 5HT₃ receptors.
- Vortioxetine also targets the serotonin transporter (SERT), 5HT_{1A}, 5HT_{1B}, 5HT_{1D}, and 5HT₇ receptors.
- 5HT₃ antagonism enhances not only the release of 5HT, but also of norepinephrine (NE) and acetylcholine (ACh), which may be linked to its antidepressant and procognitive properties.

Vortioxetine is a “multimodal” agent that simultaneously acts at 6 pharmacologic targets with 3 modes of action (Figure 1)^{1–4}:

1. Inhibition of the serotonin (5HT) transporter or SERT
2. Actions at several G-protein linked receptors (agonist actions at 5HT_{1A} receptors, partial agonist actions at 5HT_{1B} receptors, antagonist actions at 5HT_{1D} and 5HT₇ receptors)
3. Inhibition of a ligand-gated ion channel (the 5HT₃ receptor)


We have previously described the mechanisms whereby vortioxetine’s actions at 5HT receptors work together to enhance the release of 5HT⁵ and glutamate⁶ and to inhibit the release of GABA (gamma amino butyric acid).⁶ Here we discuss how antagonism of 5HT₃ receptors by vortioxetine (Figure 1) is one of the hypothetical mechanisms that also leads to enhanced release of 5HT as well as to enhanced release of NE and ACh.^{3,4,7,8} An explanation of vortioxetine’s hypothetical actions at additional 5HT receptors that also contribute to the enhanced release of NE and ACh, as well as to the release of DA and histamine HA, has been discussed elsewhere.^{3,4,7,8}

Serotonin and Glutamate Regulate Each Other

It is well known that 5HT regulates its own release via feedback mediated by autoreceptors that are located on the 5HT neurons themselves.^{5,9,10} However, 5HT can also regulate its own release via postsynaptic 5HT₃ receptors located within a 3-neuron feedback loop (Figure 2A).^{10–15} The first neuron in this feedback loop is serotonergic, and provides input to prefrontal




Figure 1. Icon of vortioxetine showing its 6 pharmacologic mechanisms. Highlighted here is 5HT₃ antagonism, linked to enhanced release of serotonin (5HT), NE, and ACh.



cortex and hippocampus. There, 5HT stimulates excitatory 5HT₃ receptors on a GABAergic interneuron (Figure 2A). This second neuron in the feedback loop is a type of GABAergic interneuron that does not stain positively for the calcium binding protein parvalbumin and is regular spiking, late spiking, or bursting in its firing pattern.^{6,10–28} The GABA that is released from this second neuron in turn inhibits the third neuron in the feedback loop, namely, a pyramidal neuron in the prefrontal cortex or hippocampus (Figure 2A). This pyramidal neuron finally projects back to the midbrain raphe where it can release glutamate and stimulate 5HT release (Figure 2A). Thus, 5HT regulates downstream glutamate release, which in turn regulates 5HT release (Figure 2A).

Although SSRIs increase 5HT levels by SERT inhibition, activation of 5HT₃ receptors by 5HT in this feedback loop leads to inhibition of cortical pyramidal neurons due to activation of GABAergic inhibition, and thus no amplification of 5HT release by downstream glutamate (Figure 2B).^{10–15} Contrast this with vortioxetine, which not only enhances 5HT via SERT inhibition, but also blocks 5HT₃ receptors (Figure 2C). 5HT₃ receptor antagonism removes GABAergic inhibition and thus disinhibits pyramidal neurons, further enhancing 5HT release by glutamatergic stimulation of serotonergic neurons in the midbrain raphe (Figure 2C).^{3,4,16,17}

Figure 2A. Serotonin and glutamate regulate each other: role of 5HT₃ receptors. Shown here is a 3-neuron feedback circuit, beginning with the 5HT neuron, terminating upon a 5HT₃ receptor localized upon a second neuron: a GABAergic interneuron that does not stain positively for the calcium binding protein parvalbumin and has a firing pattern that is regular spiking, late spiking or bursting. GABA released from this second neuron in turn inhibits the third neuron in this feedback circuit: cortical pyramidal neurons that release glutamate at nerve terminals that project back to the midbrain raphe and that stimulate 5HT release.




Serotonergic Regulation of Norepinephrine (NE) and Acetylcholine (ACh) Release

5HT regulates the downstream release of many neurotransmitters, not only 5HT itself, but also NE, ACh, DA, and HA.^{3,4,9,10,18,24} Stimulation of postsynaptic 5HT_{1A} receptors increases cortical and hippocampal release of ACh^{29,30} and NE.^{31,32} Although the microanatomy is still being worked out, blockade of postsynaptic serotonergic heteroreceptors on presynaptic nerve terminals could theoretically be another mechanism whereby ACh, NE, DA, and HA release is enhanced.^{8,10} These various mechanisms are discussed elsewhere.^{3,4,7–10} Here we discuss and illustrate how 5HT₃ receptors regulate both NE and ACh release. Specifically, 5HT stimulation of 5HT₃ receptors causes inhibitory output from GABAergic interneurons, and this inhibits the release of NE and ACh from presynaptic nerve terminals (Figure 3A).^{19,20} Thus, when SSRIs elevate 5HT levels, this causes GABA to be released,



BRAINSTORMS—Clinical Neuroscience Update Part 3

Figure 2B. When 5HT levels increase after administration of an SSRI, the activation of 5HT receptors by 5HT leads to stimulation of GABA release; this in turn inhibits cortical pyramidal neurons, and thus there is no amplification of 5HT release by downstream glutamate.



which in turn inhibits both NE and ACh release (Figure 3B).^{19,20} By contrast, vortioxetine blocks the 5HT₃ receptor so that GABA is not released by 5HT, and therefore both NE and ACh are disinhibited—ie, their levels are enhanced (Figure 3C).^{2,8}

Potential Clinical Significance of 5HT₃ Antagonism

Enhanced release of 5HT by combining 5HT₃ antagonism with SERT inhibition likely contributes to the antidepressant actions of vortioxetine.^{1–4,8,24} Enhanced 5HT release by combining SERT inhibition with several of vortioxetine’s other actions at 5HT receptors—namely 5HT_{1A} agonism, 5HT_{1B} partial agonism, 5HT_{1D} antagonism, and 5HT₇ antagonism—was discussed in a previous Brainstorms article.⁵ Enhanced release of NE and ACh levels is also likely an important feature of vortioxetine’s clinical activity. That is, NE and ACh levels are increased with selective 5HT₃ antagonists that also exhibit procognitive activity in animal models.^{33–37} Thus, vortioxetine’s procognitive actions in both animal models^{24,38–41} and in patients with major depressive disorder^{42–44} may be mediated in part by its 5HT₃ antagonist properties and the enhanced release of both NE and ACh that accompany 5HT₃ receptor antagonism. Adding 5HT₃ antagonist

Figure 2C. In contrast to the actions of SSRIs shown in Figure 2B, shown here are the actions of vortioxetine, which not only enhance 5HT via SERT inhibition, but also block 5HT₃ receptors. The blockade of 5HT₃ receptors removes GABA inhibition and thus disinhibits pyramidal neurons. This in turn enhances downstream release of 5HT due to glutamatergic stimulation of serotonergic neurons in the midbrain raphe.




Figure 3A. Serotonin (5HT) 3 receptor mediated regulation of ACh and NE release. 5HT stimulation of 5HT₃ receptors causes inhibitory output from GABAergic interneurons, and this inhibits the release of NE and ACh from presynaptic nerve terminals.






Figure 3B. SSRIs inhibit the release of ACh and NE via 5HT₃ receptors. When SSRIs increase 5HT levels by SERT inhibition, GABA is released, which in turn inhibits both NE and ACh release.





Figure 3C. Vortioxetine enhances the release of ACh and NE by blocking 5HT₃ receptors. By contrast with SSRI actions shown in Figure 3B, vortioxetine blocks the 5HT₃ receptor so that GABA is not released by 5HT, and therefore both NE and ACh are disinhibited—ie, their levels are enhanced.



to SSRI actions could potentially enhance not only the antidepressant actions of SSRI activity but also add procognitive actions to antidepressant actions via increased release of 5HT, ACh, and NE. This possibility

fits with the notion that neurotransmitters may theoretically “tune” the malfunctioning brain circuits that cause psychiatric symptoms.^{6,16,45,46} The release of 5HT, NE, and ACh by vortioxetine could theoretically improve the efficiency of information processing in maladaptive brain circuits by facilitating long-term potentiation, synaptic plasticity, and enhanced pyramidal neuron activity leading to improvement not only of mood but also of cognitive symptoms in major depressive disorder.

References:

- Mørk A, Pehrson A, Brennum LT, *et al.* Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. *J Pharmacol Exp Ther.* 2012; **340**(3): 666–675.
- Bang-Andersen B, Ruhland T, Jorgensen M, *et al.* Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. *J Med Chem.* 2011; **54**(9): 3206–3221.
- Pehrson AL, Cremers T, Bétry C, *et al.* Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters—a rat microdialysis and electrophysiology study. *Eur Neuropsychopharmacol.* 2013; **23**(2): 133–145.
- Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. *Pharmacol Ther.* 2015; **145**: 43–57.
- Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with action at 5HT receptors (5HT_{1A}, 5HT_{1B}, 5HT_{1D}, 5HT₇ receptors). *CNS Spectr.* 2015; **20**(2): 93–97.
- Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): modifying serotonin’s downstream effects on glutamate and GABA (gamma-aminobutyric acid) release by blocking 5HT₃ and 5HT₇ receptors. *CNS Spectr.* In press.
- Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters. *CNS Spectr.* In press.
- Mørk A, Montezinho LP, Miller S. Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. *Pharmacol Biochem Behav.* 2013; **105**: 41–50.
- Stahl SM. *Stahl’s Essential Psychopharmacology*. 4th ed. Cambridge, UK: Cambridge University Press; 2013.
- Fink KB, Gothert M. 5HT receptor regulation of neurotransmitter release. *Pharmacol Rev.* 2007; **59**(4): 360–417.
- Gehlert DR, Gackenheim SL, Wong DT, Robertson DW. Localization of 5-HT₃ receptors in the rat brain using [3H] LY278584. *Brain Res.* 1991; **553**(1): 149–154.
- Puig MV, Santana N, Celada P, Mengod G, Artigas F. In vivo excitation of GABA interneurons in the medial prefrontal cortex through 5-HT₃ receptors. *Cereb Cortex.* 2004; **14**(12): 1365–1375.
- Morales M, Battenberg E, Bloom FE. Distribution of neurons expressing immunoreactivity for the 5HT₃ receptor subtype in the rat brain and spinal cord. *J Comp Neurol.* 1998; **402**(3): 385–401.



BRAINSTORMS—Clinical Neuroscience Update Part 3

14. Morales M, Bloom FE. The 5-HT₃ receptor is present in different subpopulations of GABAergic neurons in the rat telencephalon. *J Neurosci*. 1997; **17**(9): 3157–3167.
15. Ashby CR Jr, Minabe Y, Edwards E, Wang RY. 5-HT₃-like receptors in the rat medial prefrontal cortex: an electrophysiological study. *Brain Res*. 1991; **550**(2): 181–191.
16. Dale E, Zhang H, Leiser S, *et al*. Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in rat hippocampus. *J Psychopharmacol*. 2014; **28**(10): 891–902.
17. Bétry C, Pehrson AL, Etievant A, *et al*. The rapid recovery of 5HT cell firing induced by the antidepressant vortioxetine involves 5HT₃ receptor antagonism. *Int J Neuropsychopharmacol*. 2013; **16**(5): 1115–1127.
18. Artigas F. Serotonin receptors involved in antidepressant effects. *Pharmacol Ther*. 2013; **137**(1): 119–131.
19. Matsumoto M, Yoshioka M, Togashi H, Tochiyama M, Ikeda T, Saito H. Modulation of norepinephrine release by serotonergic receptors in the rat hippocampus as measured by in vivo microdialysis. *J Pharmacol Exp Ther*. 1995; **272**(3): 1044–1051.
20. Yan Z. Regulation of GABAergic inhibition by serotonin signaling in prefrontal cortex: molecular mechanisms and functional implications. *Mol Neurobiol*. 2002; **26**(2–3): 203–216.
21. Siarey RJ, Andreasen M, Lambert JDC. Serotonergic modulation of excitability in area CA1 of the in vitro rat hippocampus. *Neurosci Lett*. 1995; **199**(3): 211–214.
22. Zhou F, Hablitz JJ. Activation of serotonin receptors modulates synaptic transmission in rat cerebral cortex. *J Neurophysiol*. 1999; **82**(6): 2989–2999.
23. Giovannini MG, Ceccarelli I, Molinari B, Cecci M, Goldfarb J, Blandina P. Serotonergic modulation of acetylcholine release from cortex of freely moving rats. *J Pharmacol Exp Ther*. 1998; **285**(3): 1219–1225.
24. Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. *CNS Spectr*. 2014; **19**(2): 121–133.
25. Puig MV, Gullledge AT. Serotonin and prefrontal cortex function: neurons, networks, and circuits. *Mol Neurobiol*. 2011; **44**(3): 449–464.
26. Kubota Y. Untangling GABAergic wiring in the cortical microcircuit. *Curr Opin Neurobiol*. 2014; **26**: 7–14.
27. Adesnik H, Scanziani M. Lateral competition for cortical space by layer-specific horizontal circuits. *Nature*. 2010; **464**(7292): 1155–1160.
28. Gottlieb JP, Keller A. Intrinsic circuitry and physiological properties of pyramidal neurons in rat barrel cortex. *Exp Brain Res*. 1997; **115**(1): 47–60.
29. Izumi J, Washizuka M, Miura N, Hiraga Y, Ikeda Y. Hippocampal serotonin 5HT_{1A} receptor enhances acetylcholine release in conscious rats. *J Neurochem*. 1994; **62**(5): 1804–1808.
30. Consolo S, Ramponi S, Ladinsky H, Baldi G. A critical role for D1 receptors in the 5HT_{1A}-mediated facilitation of in vivo acetylcholine release in rat frontal cortex. *Brain Res*. 1996; **707**: 320–323.
31. Suzuki M, Matsuda T, Asano S, Somboonthum P, Takuma K, Baba A. Increase of noradrenaline release in the hypothalamus of freely moving rat by postsynaptic 5-hydroxytryptamine 1A receptor activation. *Br J Pharmacol*. 1995; **115**(4): 703–711.
32. Suwabe A, Kubota M, Niwa M, Kobayashi K, Kanba S. Effect of a 5HT_{1A} receptor agonist, flesinoxan, on the extracellular noradrenaline level in the hippocampus and on the locomotor activity of rats. *Brain Res*. 2000; **858**(2): 393–401.
33. Brambilla A, Ghiorzi A, Pitsikas N, Borsini F. DAU 6215, a novel 5HT₃ receptor antagonist selectively antagonizes scopolamine-induced deficit in a passive avoidance task, but not scopolamine induced hypermotility in rats. *J Pharm Pharmacol*. 1993; **45**(9): 841–843.
34. Fontana DJ, Daniels SE, Henderson C, Eglén RM, Wong EH. Ondansetron improves cognitive performance in the Morris water maze spatial navigation task. *Psychopharmacol (Berl)*. 1995; **120**(4): 409–417.
35. Pitsikas N, Borsini F. Itasetron (DAU 6215) prevents age-related memory deficits in the rat in a multiple choice avoidance task. *Eur J Pharmacol*. 1996; **311**(2–3): 115–119.
36. Roychoudhury M, Kulkarni SK. Effects of ondansetron on short-term memory retrieval in mice. *Methods Find Exp Clin Pharmacol*. 1997; **19**(1): 43–46.
37. Arnsten AF, Line CH, Van Dyck CH, Stanhope KJ. The effects of 5HT₃ receptor antagonists on cognitive performance in aged monkeys. *Neurobiol Aging*. 1997; **18**(1): 21–28.
38. du Jardin KG, Jensen JB, Sanchez C, Pehrson AL. Vortioxetine dose dependently reverses 5HT depletion induced deficits in spatial working and object recognition memory: a potential role of 5HT_{1A} receptor agonism and 5HT₃ receptor antagonism. *Eur Neuropsychopharmacol*. 2014; **24**(1): 160–171.
39. Jensen JB, du Jardin KG, Song D, *et al*. Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5HT depletion in rats: evidence for direct 5HT receptor modulation. *Eur Neuropsychopharmacol*. 2014; **24**(1): 148–159.
40. Li Y, Sanchez C, Gulinello M. Memory impairment in old mice is differentially sensitive to different classes of antidepressants. *Eur Neuropsychopharmacol*. 2013; **23**(Suppl 2): S282.
41. Wallace A, Pehrson AL, Sánchez C, Morilak DA. Vortioxetine restores learning impaired by 5HT depletion or chronic intermittent cold stress in rats. *Int J Neuropsychopharmacol*. 2014; **17**(10): 1695–1706.
42. Katona C, Hansen T, Olsen CK. A randomized, double blind, placebo controlled, duloxetine referenced, fixed dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. *Int Clin Psychopharmacol*. 2012; **27**(4): 215–223.
43. McIntyre RS, Lophaven S, Olsen C. A randomized, double-blind, placebo controlled study of vortioxetine on cognitive function in depressed adults. *Int J Neuropsychopharmacol*. 2014; **17**(10): 1557–1567.
44. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RSE. A randomized, placebo-controlled, active-reference, double blind, flexible dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. *Neuropsychopharmacology*. In press. DOI: 10.1038/npp.2015.52.
45. Insel T, Cuthbert B, Garvey M, *et al*. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. *Am J Psychiatry*. 2010; **167**(7): 748–751.
46. Stahl SM. The last diagnostic and statistical manual (DSM): replacing our symptom-based diagnoses with a brain circuit-based classification of mental illnesses. *CNS Spectr*. 2013; **18**(2): 65–68.